Astrazeneca Ab

Sortina Pharma Ab

Thomas Olsson

Peter Guzzo

Sverker Von Unge

Marianne Swanson

Thomas Elebring

Jan Mattsson

Kosrat Amin

Wayne Brailsford

Udo Bauer

Linda Gustafsson

Karolina Nilsson

Vijay Chhajlani

Bryan Egner

Ola Fjellström

Anders Holmén

Sara Rhost

The present invention relates to novel compounds having a positive allosteric G&#xc0;BAB receptor (GDR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). A compound of the general formula I. 

Imidazole variants as modulators of GABA receptor for the treatment of GI disorders

Intermediates used in the preparation of compounds of formula I,or a stereoisomer thereof, or a pharmaceutically acceptable form of either selected from the group consisting of a salt, a solvate and a combination thereof,with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S,3R)-(3-amino-2-hydroxybutyl)phosphinic acid.

Aminopropylphosphinic acids

(Aminopropyl)methylphosphinic acids

Growing community of inventors

Torslanda, Sweden

Thomas Olsson